A bipartisan coalition of 39 attorneys general is urging Congress to set new limits and transparency requirements for pharmacy benefit managers, the companies that manage drug benefits for insurers and employers.
A letter to U.S. House and Senate leaders dated Wednesday argued that states have taken aggressive steps in recent years to address opaque business practices and market consolidation that have been blamed for artificially inflating prescription drug prices.
Already a subscriber? Sign in